Lionel C.
- Country
- France
- Department
- Service de Néphrologie - Transplantation - Dialyse
Research Overview
- Frexalimab Versus Tacrolimus for Prevention of Kidney Graft Rejection in Adult Kidney Transplant Recipients
- Phase 2 Study of Empasiprubart in Deceased Donor Renal Allograft Recipients at Risk for Delayed Graft Function
- Evaluation of Intravenous Human Normal Immunoglobulin for Prevention of BK Virus Viremia in Kidney Transplant Recipients with Low Neutralizing Antibody Titers
Data & Insights
Has run more than one trial at 81 of 176 partner sites.
Specializations
Kidney Transplantation Management
This investigator specializes in advancing therapeutic approaches for kidney transplant recipients, with particular focus on managing post-transplant complications and improving graft survival outcomes.
- Delayed Graft Function Prevention
- Antibody-Mediated Rejection Treatment
- BK Virus Prevention Strategies
Their work encompasses innovative approaches to transplant immunology and prevention of viral complications in transplant recipients.
Lupus Nephritis Treatment
The investigator demonstrates significant expertise in treating lupus nephritis, exploring various therapeutic modalities and novel treatment approaches.
- Proliferative Lupus Nephritis Management
- Corticosteroid-Free Protocols
- Innovative Biological Therapies
Their research encompasses both traditional and emerging therapeutic options for lupus-related kidney disease.
Transplant Immunology
The investigator focuses on understanding and modulating transplant immunological responses, particularly in sensitized recipients and viral infection management.
- EBV-Related Complications
- Immunosuppression Protocols
- Antibody-Mediated Rejection Prevention
Their work includes development of targeted immunological interventions in transplant recipients.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.